Market Data 
Markets
Replies to post #136957 on Biotech Values
02/24/12 3:53 PM
“There is no question that the economic environment has changed dramatically over the last few years. The cost consciousness of payers and those that reimburse drugs has put pressure on the FDA. Although the FDA's mandate says that it is not required to look at the cost-effectiveness of individual medications, there is much more of an acceptance of the fact that it is no longer sufficient of developers of products to simply demonstrate safety and efficacy. They have to demonstrate some sort of cost value. And I think, although the FDA is not mandated to review that information they still feel that pressure.”
—Kenneth Kaitin, Director, Tufts Center for the Study of Drug Development
06/26/12 12:34 PM
The number of innovative medicines, or new molecular entities, launched globally in 2011 hit a 10-year high of 31, up from 21 in 2010.
…the tally of drugs terminated in the final Phase III stage of clinical trials dropped markedly, to 45 in the last three years from 53 in 2008-2010…
R&D expenditure on prescription drugs has effectively plateaued in the past four years, after decades of relentless increases… leading drugmakers spent an aggregate $71.05 billion in 2011. That was 2.5 percent more than in 2010, although part of the rise reflected weakness in the dollar, since a large part of global R&D cash is spent in euros and Swiss francs.
AI
